Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pazopanib after prior sunitinib failure in metastatic or unresectable renal cell carcinoma
2010-022770-13Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC), sponsored by Cancer Trials Ireland. Primary endpoint: Progression-free rate at 4 months. Started Oct 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2010-022770-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022770-13.